DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Dihydro (Dihydrocodeine Bitartrate / Chlorpheniramine Maleate / Pseudoephedrine Hydrochloride) - Summary

 
 



DIHYDRO SUMMARY

Antitussive/Antihistamine/Decongestant
Rx Only
CIII

This product is indicated for the temporary relief of cough and nasal congestion associated with upper respiratory tract infections and allergies.

See all Dihydro indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Dihydro (Dihydrocodeine / Chlorpheniramine / Pseudoephedrine)

DC Week: Payment Update from CMS, FDA Eyes Codeine Cough Syrups
Source: MedPageToday.com - medical news plus CME for physicians [2015.07.03]
(MedPage Today) -- Also: House members question CMS fraud prevention strategies

FDA Reviewing Safety of Codeine for Cough in Kids Under 18
Source: Medscape Emergency Medicine Headlines [2015.07.01]
The FDA is investigating the safety of using codeine-containing medicines to treat coughs and colds in children younger than 18 years because of the potential for serious adverse effects.
News Alerts

FDA Probes Kids' Codeine Cough Syrups
Source: MedPage Today Pediatrics [2015.07.01]
(MedPage Today) -- New European report raises questions about safety of codeine products for younger children.

Study: Whooping cough resurgence due to vaccinated people not knowing they're infectious?
Source: Immune System / Vaccines News From Medical News Today [2015.06.24]
Whooping cough has made an astonishing comeback, with 2012 seeing nearly 50,000 infections in the U.S.

Cough
Source: MedicineNet Alpha 1 Antitrypsin Deficiency Specialty [2015.06.16]
Title: Cough
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 6/16/2015 12:00:00 AM

more news >>

Published Studies Related to Dihydro (Dihydrocodeine / Chlorpheniramine / Pseudoephedrine)

13,14-Dihydro-15-keto prostaglandin F2alpha release in response to oxytocin challenge early post-partum in anoestrous Nelore cows submitted to temporary calf removal and progesterone priming. [2010.10]
The study evaluated, in early post-partum anoestrous Nelore cows, if the increase in plasma oestradiol (E2) concentrations in the pre-ovulatory period and/or progesterone priming (P4 priming) preceding ovulation, induced by hormonal treatment, reduces the endogenous release of prostaglandin PGF(2)alpha and prevents premature lysis of the corpus luteum (CL).

Luteal blood flow and concentrations of circulating progesterone and other hormones associated with a simulated pulse of 13,14-dihydro-15-keto-prostaglandin F2alpha in heifers. [2010.03]
Progesterone and luteal blood flow effects of an i.u. 2-h infusion of 0.25 mg/h of prostaglandin F(2)(alpha) (PGF) that simulated a natural pulse of 13,14-dihydro-15-keto-PGF (PGFM) were compared to the effects of a single bolus i.u... The comparisons between progesterone and blood flow are novel.

An inhibitory metabolite leads to dose- and time-dependent pharmacokinetics of (R)-N-{1-[3-(4-ethoxy-phenyl)-4-oxo-3,4-dihydro-pyrido[2,3-d]pyrimidin-2-yl]-ethyl}-N-pyridin-3-yl-methyl-2-(4-trifluoromethoxy-phenyl)-acetamide (AMG 487) in human subjects after multiple dosing. [2009.03]
(R)-N-{1-[3-(4-Ethoxy-phenyl)-4-oxo-3,4-dihydro-pyrido[2,3-d]-pyrimidin-2-yl]-ethyl}-N-pyridin-3-yl-methyl-2-(4-trifluoromethoxyphenyl)-acetamide (AMG 487) is a potent and selective orally bioavailable chemokine (C-X-C motif) receptor 3 (CXCR3) antagonist that displays dose- and time-dependent pharmacokinetics in human subjects after multiple oral dosing...

Effect of dose of estradiol-17beta on prominence of an induced 13,14-dihydro-15-keto-PGF(2alpha) (PGFM) pulse and relationship of prominence to progesterone, LH, and luteal blood flow in heifers. [2011.08]
Various doses of estradiol-17beta (E(2)) were used in heifers to induce a pulse of 13,14-dihydro-15-keto-prostaglandin F(2alpha) (PGFM). The effect of E(2) concentration on the prominence of PGFM pulses and the relationship between prominence and intrapulse concentration of progesterone (P(4)), LH, and luteal blood flow were studied...

Mixture of cis-3-hexenol and trans-2-hexenal attenuates behavioral and stress responses induced by 2,5-dihydro-2,4,5-trimethylthiazoline and electric footshock stress in rats. [2011.07.06]
Green odor (GO), a mixture of cis-3-hexenol and trans-2-hexenal, attenuates stress responses and anxiety to psychological stressors in rodents; however, it remains unknown whether GO affects behavioral and stress responses to risk-related olfactory stimuli and actual noxious stimuli...

more studies >>

Clinical Trials Related to Dihydro (Dihydrocodeine / Chlorpheniramine / Pseudoephedrine)

[18F] Dihydro-testosterone Pet and MR Imaging In Patients With Localized Prostate Cancer [Recruiting]
The purpose of this study is to test the ability of a new PET scan radiotracer, called FDHT (stands for [18F] Dihydro-Testosterone), to better find and monitor prostate cancer. Radiotracers are a type of drug that carries small amounts of radioactivity that can be seen by the PET scanner. FDHT is a radiotracer that looks for a protein which is present in almost all prostate cancer cells. The investigators want to find out if we can find and monitor changes in cancer using a FDHT PET scan.

[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer [Recruiting]
This study will use PET scans, which is a type of x-ray test that uses a radiotracer, to see whether these scans may be better able to find places in the body where your prostate cancer may have spread.

The Effects of Caffeine on Force Loss Following Exercise-induced Muscle Damage [Not yet recruiting]
We have hypothesized: 1) Caffeine will increase maximal voluntary strength compared to placebo in undamaged muscle. 2) Caffeine will increase muscle activation compared to placebo in undamaged muscle. 3) Caffeine will enhance spinal excitability (indicated by an enhanced H-reflex) compared to placebo in undamaged muscle. 4) Caffeine will raise the pressure-pain threshold (indicating decreased pain sensitivity) in the calf muscle compared to placebo in undamaged muscle. 5) Caffeine will reduce the amount of low-frequency fatigue, indicated by an enhanced 20-100 hertz strength ratio, compared to placebo in undamaged muscle. 6) Caffeine will increase maximal voluntary strength compared to placebo in damaged muscle. 7) Caffeine will increase muscle activation compared to placebo in damaged muscle. 8) Caffeine will enhance spinal excitability (indicated by an enhanced H-reflex) compared to placebo in damaged muscle. 9) Caffeine will raise the pressure-pain threshold (indicating decreased pain sensitivity) in the calf muscle compared to placebo in damaged muscle. 10) Caffeine will reduce the amount of low-frequency fatigue, indicated by an enhanced 20-100 hertz strength ratio, compared to placebo in damaged muscle. The proposed research will determine the effects of a 5mg/kg body weight dose of caffeine on muscular strength, activation, H-reflex function, and excitation-contraction coupling before and after exercise-induced muscle damage. The long term objectives are to gain a better understanding of caffeine and its affects following exercise-induced muscle damage allowing us to understand how caffeine is mechanistically interacting with functions of the body.

Beneficial Effects of Exercise and Healthy Diets on Muscle and Adipose Tissue [Not yet recruiting]
Both dietary caloric restriction (CR) and physical exercise (PE) exert beneficial effects, which retard or prevent age-related diseases and prolong life span. Subjects with the metabolic syndrome age prematurely, therefore preventive measures should be initiated early. The present study intends to demonstrate that physical exercise and/or Mediterranean diet, in middle aged volunteers with the metabolic syndrome, preserve adequate adipose tissue functionality and retard skeletal muscle aging (assessed by mitochondrial biogenesis and accumulation of ROS), by activating several pathways, homologous to CR. The investigators plan to study this by using two approaches: 1) A cross- sectional model, in which the expression of the mentioned metabolic mediators, indicators of muscle mitochondrial biogenesis and muscle oxidative damage will be compared between men with different body compositions, fat distribution, muscle strength and exercise capacity (VO2max). Also, in these men the investigators will assess the expression of uncoupling protein 1 (UCP1) in subcutaneous white adipose tissue (as a measure of adaptive thermogenesis), and inflammatory markers (Interleukin 1-6, Interleukin 1├č and CCL2 chemokine (C-C motif ligand 2)) in preperitoneal adipose tissue, plus inflammation and adipogenesis potential of their cultured preadipocytes. Moreover, in vitro studies will evaluate the functional effects of exposure of a cell lyne of human adipocyte cells (LS14)to factors secreted by media conditioned by the patients┬┤ adipose tissue explants. 2) A prospective intervention in overweight/moderately obese middle aged volunteers that will be assigned to a weight-maintenance period (as a control group), and then randomly y assigned to a Mediterranean diet, exercise training or diet plus training. Before and after 3 months of intervention the investigators will obtain muscle tissue samples to study the expression of Peroxisome proliferator activated receptor (PPAR) gamma coactivator 1 alpha (PGC1), uncoupling protein 3 (UCP3), AMP activated protein kinase (AMPK), Sirtuin 1 (SIRT-1), mitochondrial DNA and oxidative damage indicators (8-oxo-7,8-dihydro-2-deoxyguanosine (oxodG), carboxymethyllysine (CML and its receptor (RAGE)). In vitro studies will evaluate the effect of circulating factors from the patients (serum) on LS14 inflammatory and adipogenic potential, at baseline and after 3 months of intervention.

Efficacy and Safety of Levofloxacin for the Treatment of MDR-TB [Not yet recruiting]
Multi-drug-resistant tuberculosis (MDR-TB) affects nearly 600,000 persons each year around the world. This type of tuberculosis is very difficult to treat, and many patients die from it. Drugs of the fluoroquinolone class are very important for treating MDR-TB, but the best dose of one of the most effective fluoroquinolones, levofloxacin, is not known. This application proposes a study to determine the best dose of levofloxacin to use in treating MDR-TB. 100 patients will receive their usual treatment, plus levofloxacin at one of four doses. The study will be performed in Peru and in South Africa, where MDR-TB is common.

more trials >>


Page last updated: 2015-07-03

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015